Murman, Daniel L.; Colenda, Christopher C. - In: PharmacoEconomics 23 (2005) 3, pp. 227-242
The majority of patients with Alzheimer's disease (AD) will have clinically significant neuropsychiatric symptoms during the course of their disease. There is growing evidence that neuropsychiatric symptoms increase direct costs of care in patients with AD, especially the costs associated with...